SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Autologous, CAR-T, CD19

February 02, 2022

Yescarta’s Sales Grow; Gilead Prepares for Increased Manufacturing Demands; Tecartus’s EU Approval in R/R Adult ALL Faces Delays; Gilead’s Q4 2021 Earnings Call Summary

Here is a brief preview of this blast: On Tuesday, February 1, Gilead held their Q4 2021 earnings call (press release / presentation) highlighting an increase in revenue for their cell therapy franchise and Yescarta’s anticipated approval in 2L r/r LBCL. Furthermore, management highlighted Tecartus’s (CD19 CAR-T) Type II variation in the EU for r/r adult ALL. Below, Celltelligence provides insights on how Gilead’s manufacturing strategy could position the company for success, while discussing likely US and EU approvals for Yescarta in 2L LBCL.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.